Ultragenyx Pharmaceutical
RARE
77 hedge funds and large institutions have $815M invested in Ultragenyx Pharmaceutical in 2014 Q1 according to their latest regulatory filings, with 77 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
63.05% more ownership
Funds ownership: 0% → 63.05% (+63%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$185M |
| 2 |
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
+$159M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$106M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$94.8M |
| 5 |
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$92.4M |
Top Sellers
RARE Hedge Fund Activity: Q1 2014 in Review
77 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2014, worth a combined $815M.
Buyers outnumbered sellers: 77 funds opened new RARE positions and 0 closed out — a net gain of 77 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $185M.
- 77 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $815M of Ultragenyx Pharmaceutical stock for Q1 2014.
- 77 funds opened new Ultragenyx Pharmaceutical positions in Q1 2014 and 0 closed out, a net change of +77 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q1 2014 was Fidelity Investments, an estimated $185M added.
Based on aggregated 13F filings for Q1 2014.